Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection With Oral Vancomycin Compared With Metronidazole
Open accessThe DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.
Abstract
Antibiotic administration disrupts the intestinal microbiota, increasing susceptibility to pathogens such as Clostridium difficile. Metronidazole or oral vancomycin can cure C. difficile infection, and administration of these agents to prevent C. difficile infection in high-risk patients, although not sanctioned by Infectious Disease Society of America guidelines, has been considered. The relative impacts of metronidazole and vancomycin on the intestinal microbiota and colonization resistance are unknown. We investigated the effect of brief treatment with metronidazole and/or oral vancomycin on susceptibility to C. difficile, vancomycin-resistant Enterococcus, carbapenem-resistant Klebsiella pneumoniae, and Escherichia coli infection in mice. Although metronidazole resulted in transient loss of colonization resistance, oral vancomycin markedly disrupted the microbiota, leading to prolonged loss of colonization resistance to C. difficile infection and dense colonization by vancomycin-resistant Enterococcus, K. pneumoniae, and E. coli. Our results demonstrate that vancomycin, and to a lesser extent metronidazole, are associated with marked intestinal microbiota destruction and greater risk of colonization by nosocomial pathogens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“vancomycin has been shown to cause long-lasting susceptibility to a variety of secondary infections in both humans and mice [84].”
From Antibiotic-Induced Changes in the Intestinal Microbiota and Disease (2016) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549 · cited 1×
“MiSeq platform and reads were analyzed using an in-house pipeline mainly derived from the mothur software [20](see “Methods” section).”
MethodA new method for non-parametric multivariate analysis of variance
Anderson, M. J. (2001) · Austral Ecology · doi:10.1111/j.1442-9993.2001.01070.pp.x · Cited by 13,828 · cited 1×
“method [24] was used to compare samples that supported C.”
MethodGreengenes, a Chimera-Checked 16S rRNA Gene Database and Workbench Compatible with ARB
DeSantis, T. Z., Hugenholtz, P., Larsen, N., Rojas, M., Brodie, E. L., Keller, K., Huber, T., Dalevi, D., Hu, P., & Andersen, G. L. (2006) · Applied and Environmental Microbiology · doi:10.1128/aem.03006-05 · Cited by 10,891 · cited 1×
“Operational taxonomic units (OTUs) were classified with a modified Greengenes reference database [21].”
MethodUniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227 · cited 2×
“Phylogenetic trees were inferred by using Clearcut [22] on the alignment created by mothur, and then unweighted UniFrac [23] was run on”
MethodAn Epidemic, Toxin Gene–Variant Strain of Clostridium difficile
McDonald, L. C., Killgore, G. E., Thompson, A., Owens, R. C., Kazakova, S. V., Sambol, S. P., Johnson, S., & Gerding, D. N. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051590 · Cited by 2,006 · cited 1×
“number of cases, with strains emerging that produce increased amounts of toxin and are resistant to fluoroquinolone antibiotics [2, 3].”
BackgroundPrecision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile
Buffie, C. G., Bucci, V., Stein, R. R., McKenney, P. T., Ling, L., Gobourne, A., No, D., Liu, H., Kinnebrew, M., Viale, A., et al. (2015) · Nature · doi:10.1038/nature13828 · Cited by 1,872
Self-citationFidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585 · cited 1×
“In contrast to vancomycin and metronidazole, fidaxomicin has been demonstrated to have a narrower spectrum of activity against obligate anaerobes of the colon [28, 29].”
BackgroundZar, F. A., Bakkanagari, S. R., Moorthi, K. M. L. S. T., & Davis, M. B. (2007) · Clinical Infectious Diseases · doi:10.1086/519265 · Cited by 1,252
Pepin, J. (2004) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041104 · Cited by 1,128 · cited 1×
“particularly among elderly individuals living in assisted care facilities but also in the general community [5, 6].”
BackgroundClostridium difficile infection in Europe: a hospital-based survey
Bauer, M. P., Notermans, D. W., van Benthem, B. H., Brazier, J. S., Wilcox, M. H., Rupnik, M., Monnet, D. L., van Dissel, J. T., & Kuijper, E. J. (2011) · The Lancet · doi:10.1016/s0140-6736(10)61266-4 · Cited by 1,020 · cited 1×
“difficile infection [7–9].”
Ubeda, C., Taur, Y., Jenq, R. R., Equinda, M. J., Son, T., Samstein, M., Viale, A., Socci, N. D., van den Brink, M. R. M., Kamboj, M., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43918 · Cited by 943 · cited 1×
“elsewhere [18].”
Emergence and global spread of epidemic healthcare-associated Clostridium difficile
He, M., Miyajima, F., Roberts, P., Ellison, L., Pickard, D. J., Martin, M. J., Connor, T. R., Harris, S. R., Fairley, D., Bamford, K. B., et al. (2013) · Nature Genetics · doi:10.1038/ng.2478 · Cited by 735 · cited 1×
“number of cases, with strains emerging that produce increased amounts of toxin and are resistant to fluoroquinolone antibiotics [2, 3].”
BackgroundBuffie, C. G., Jarchum, I., Equinda, M., Lipuma, L., Gobourne, A., Viale, A., Ubeda, C., Xavier, J., & Pamer, E. G. (2012) · Infection and Immunity · doi:10.1128/iai.05496-11 · Cited by 596 · cited 4×
“was assessed as described elsewhere [17].”
BackgroundMethodInfluentialSlimings, C., & Riley, T. V. (2014) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkt477 · Cited by 581 · cited 1×
“difficile infection [7–9].”
Johnson, S., Louie, T. J., Gerding, D. N., Cornely, O. A., Chasan-Taber, S., Fitts, D., Gelone, S. P., Broom, C., Davidson, D. M., & for the Polymer Alternative for CDI Treatment (PACT) investigators (2014) · Clinical Infectious Diseases · doi:10.1093/cid/ciu313 · Cited by 527 · cited 1×
“Vancomycin yields a slightly higher cure rate in some patients, but concerns over cost and the emergence of vancomycin-resistant pathogens limit its use to patients with severe disease [11–13].”
BackgroundA mouse model of clostridium difficile-associated disease
Chen, X., Katchar, K., Goldsmith, J. D., Nanthakumar, N., Cheknis, A., Gerding, D. N., & Kelly, C. P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.09.002 · Cited by 510 · cited 1×
“difficile spores does not lead to infection or colonization of conventionally housed wild-type C57BL/6 mice [25, 17].”
BackgroundMeta-analysis to assess risk factors for recurrent Clostridium difficile infection
Garey, K. W., Sethi, S., Yadav, Y., & DuPont, H. L. (2008) · Journal of Hospital Infection · doi:10.1016/j.jhin.2008.08.012 · Cited by 376 · cited 1×
“difficile infection [7–9].”
Treatment of Clostridium difficile-associated disease: old therapies and new strategies
Aslam, S., Hamill, R. J., & Musher, D. M. (2005) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(05)70215-2 · Cited by 366
Ubeda, C., Lipuma, L., Gobourne, A., Viale, A., Leiner, I., Equinda, M., Khanin, R., & Pamer, E. G. (2012) · Journal of Experimental Medicine · doi:10.1084/jem.20120504 · Cited by 310 · cited 1×
“Concordant with previous studies [30], we discovered that wild-type mice purchased from the same vendor harbored different microbes depending on the date and barrier”
ResultSelf-citationHistorical Perspectives on Studies of Clostridium difficile and C. difficile Infection
Bartlett, J. G. (2008) · Clinical Infectious Diseases · doi:10.1086/521865 · Cited by 188
Clearcut: a fast implementation of relaxed neighbor joining
Sheneman, L., Evans, J., & Foster, J. A. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl478 · Cited by 185 · cited 2×
“Phylogenetic trees were inferred by using Clearcut [22] on the alignment created by mothur, and then unweighted UniFrac [23] was run on”
MethodComparative Effectiveness of Clostridium difficile Treatments: A Systematic Review
Drekonja, D. M., Butler, M., MacDonald, R., Bliss, D., Filice, G. A., Rector, T. S., & Wilt, T. J. (2011) · Annals of Internal Medicine · doi:10.7326/0003-4819-155-12-201112200-00007 · Cited by 123 · cited 1×
“Vancomycin yields a slightly higher cure rate in some patients, but concerns over cost and the emergence of vancomycin-resistant pathogens limit its use to patients with severe disease [11–13].”
Abujamel, T., Cadnum, J. L., Jury, L. A., Sunkesula, V. C. K., Kundrapu, S., Jump, R. L., Stintzi, A. C., & Donskey, C. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076269 · Cited by 108 · cited 2×
“ing spores at this early time point [16].”
BackgroundBassis, C. M., Theriot, C. M., & Young, V. B. (2014) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02262-13 · Cited by 67 · cited 1×
“infections (tigecycline) has been shown to disrupt colonization resistance in a similar manner [32].”
ResultEyre, D. W., Babakhani, F., Griffiths, D., Seddon, J., Elías, C. D. O., Gorbach, S. L., Peto, T., Crook, D. W., & Walker, A. S. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jit598 · Cited by 60 · cited 1×
“In contrast to vancomycin and metronidazole, fidaxomicin has been demonstrated to have a narrower spectrum of activity against obligate anaerobes of the colon [28, 29].”
BackgroundOwens, R. C. (2006) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.26.3.299 · Cited by 58 · cited 1×
“nerable patient populations has led to the consideration of using metronidazole or vancomycin prophylactically [15, 26].”
BackgroundWarren, C. A., van Opstal, E. J., Riggins, M. S., Li, Y., Moore, J. H., Kolling, G. L., Guerrant, R. L., & Hoffman, P. S. (2013) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00877-12 · Cited by 56 · cited 1×
“difficile symptoms, studies in mice demonstrate that it also increases recurrence rates more than metronidazole treatment [31].”
BackgroundFeuerstadt, P., Das, R. K., & Brandt, L. J. (2014) · The American Journal of Gastroenterology · doi:10.1038/ajg.2014.167 · Cited by 31 · cited 1×
“particularly among elderly individuals living in assisted care facilities but also in the general community [5, 6].”
BackgroundRodriguez, S., Hernandez, M. B., Tarchini, G., Zaleski, M., Vatanchi, M., Cardona, L. L., Castro, F., & Schneider, A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.02.040 · Cited by 22 · cited 1×
“prompted some physicians to prescribe metronidazole prophylactically to high-risk patients [14].”
BackgroundAppropriateness of empiric therapy in patients with suspected Clostridium difficile infection
Saade, E. A., Deshpande, A., Kundrapu, S., Sunkesula, V. C. K., Guerrero, D. M., Jury, L. A., & Donskey, C. J. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.803956 · Cited by 19 · cited 2×
“nerable patient populations has led to the consideration of using metronidazole or vancomycin prophylactically [15, 26].”
BackgroundPerras, C., Tsakonas, E., Ndegwa, S., Conly, J. M., Valiquette, L., & Farrah, K. (2011) · Cited by 12
Research works printed but not linked: 1
- 10.1046/j.1442-9993.2001.01070.x · DOI · Paper page
Cited by
Antibiotic-Induced Changes in the Intestinal Microbiota and Disease
Becattini, S., Taur, Y., & Pamer, E. G. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2016.04.003 · Cited by 901
“As a consequence of its profound effect on gut autochthonous (native) communities, vancomycin has been shown to cause long-lasting susceptibility to a variety of secondary infections in both humans and mice [84].”
BackgroundSelf-citationBenefaction of probiotics for human health: A review
George Kerry, R., Patra, J. K., Gouda, S., Park, Y., Shin, H.-S., & Das, G. (2018) · Journal of Food and Drug Analysis · doi:10.1016/j.jfda.2018.01.002 · Cited by 898
Factors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
The intestinal microbiota: Antibiotics, colonization resistance, and enteric pathogens
Kim, S., Covington, A., & Pamer, E. G. (2017) · Immunological Reviews · doi:10.1111/imr.12563 · Cited by 741
Clostridium difficile colitis: pathogenesis and host defence
Abt, M. C., McKenney, P. T., & Pamer, E. G. (2016) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2016.108 · Cited by 551
Metadata
- Authors
- Lewis, B. B., Buffie, C. G., Carter, R. A., Leiner, I., Toussaint, N. C., Miller, L. C., Gobourne, A., Ling, L., & Pamer, E. G.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Lewis, Brittany B.
- Venue
- Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-04-28
- Volume
- 212
- Issue
- 10
- Pages
- 1656-1665
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- PMC
- PMC4621244
- OpenAlex
- W2149215043
- Cited by
- 197
- References
- 32
- Citations by year
- 2026: 3 · 2025: 12 · 2024: 13 · 2023: 9 · 2022: 16 · 2021: 23 · 2020: 26 · 2019: 24 · 2018: 27 · 2017: 15 · 2016: 23 · 2015: 5
- FWCI
- 18.05
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (NIH) (R01 AI42135, AI95706)
- the Tow Foundation
- a Medical Scientist Training Program
- the National Institute of General Medical Sciences
- NIH (T32GM07739)
- the Weill Cornell/Rockefeller/Sloan Kettering Tri-institutional MD-PhD Program
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Keywords
- Clostridium difficile infection, colonization resistance, gut microbiota, oral vancomycin, metronidazole, antibiotic-induced dysbiosis, vancomycin-resistant enterococci, carbapenem-resistant Klebsiella pneumoniae, Escherichia coli, nosocomial pathogens, mouse model
- MeSH terms
- Animals, Anti-Infective Agents, Bacterial Infections, Disease Models, Animal, Escherichia coli, Female, Klebsiella pneumoniae, Metronidazole, Mice, Inbred C57BL, Vancomycin, Clostridioides difficile, Disease Resistance, Vancomycin-Resistant Enterococci
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.